| Over a week ago | ||||
Morgan Stanley analyst… Morgan Stanley analyst Alex Gibson lowered the firm's price target on Grifols to EUR 34 from EUR 37 and keeps an Overweight rating on the shares. | ||||
Berenberg analyst Tom… Berenberg analyst Tom Jones lowered the firm's price target on Grifols to EUR 25.45 from EUR 26.20 and keeps a Buy rating on the shares. | ||||
HSBC analyst Stephen… HSBC analyst Stephen McGarry upgraded Grifols to Hold from Reduce with a EUR 27.30 price target. | ||||
Citi analyst Peter… Citi analyst Peter Verdult downgraded Grifols to Sell from Neutral with a EUR 25 price target. The analyst sees potential for the company's revenue and margins to keep missing expectations. | ||||
| Over a month ago | ||||
As a result of the… As a result of the current situation derived from the COVID-19, Grifols has assessed its best estimate based on the information available to date of its potential impacts in accordance with International Financial Reporting Standards. According to the evaluation, Grifols estimated a total impact of 200M euros for the fiscal year 2020. "This impact, which is mainly related to inventory valuation, will be recognized on the gross margin line of the consolidated profit and loss for the first half of 2020," the company said in a statement. In parallel, Grifols has implemented a "containment plan of non-structural operating expenses" to mitigate the impact, estimated to have a positive effect of 100M euros on its consolidated profit and loss of the 2020 financial year. | ||||
Barclays analyst Emily… Barclays analyst Emily Field lowered the firm's price target on Grifols to EUR 35 from EUR 36 and keeps an Overweight rating on the shares. | |
Grifols has signed with… Grifols has signed with banks that were part of its debt refinancing in November 2019 an upsize of its multicurrency revolving credit facility from $500M to $1B, with maturity in November 2025. Terms and Conditions are in line with those signed in November 2019. "The purpose of the upsize of the RCF, which has not yet being withdrawn, is to reinforce the liquidity position of the Company to reach an amount up to EUR 1,700 million," Grifols noted in a statement. | |
Grifols has received FDA… Grifols has received FDA approval for the Procleix Panther System featuring ART for use with the following U.S. licensed products: Procleix Ultrio Elite Assay, Procleix WNV Assay, Procleix Zika Virus Assay and the Procleix Babesia Assay. ART supports laboratory efforts to reach complete sample automation. The Procleix Panther System featuring ART has been available since October 2019 in all markets accepting the CE-mark. | |
JPMorgan analyst James… JPMorgan analyst James Gordon last night downgraded Grifols to Neutral from Overweight with a price target of $21, down from $25.50. The analyst no longer sees positive earnings momentum and believes the current valuation fully reflects the company's "strong" medium-term outlook. Further, longer-term competitive threats will prevent any further multiple expansion, Gordon tells investors in a research note. | |
JPMorgan analyst James… JPMorgan analyst James Gordon downgraded Grifols to Neutral from Overweight with a $21 price target. The current valuation does not reflect the company's longer term competitive threats, Gordon tells investors in a research note. |